Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing. The study provides key insights on the transforming pharmaceutical value chain, with the adoption of technology and shift towards digitalisation of key processes across drug development and manufacturing. It analyses the dynamics catalysing growth, profiles organisations presenting significant growth opportunities, and outlines innovative industry trends of key participants who play a vital role in the pharmaceutical landscape. The research covers the top 5 APAC pharmaceutical companies based on their industry position. The companies included in the study are Takeda, Otsuka, Astellas Pharma, Meiji Seika, and Celltrion. These companies are benchmarked across 5 key growth levers, namely, core areas of focus, digital footprint, value chain excellence, strategic collaborations and partnerships, and beyond-the-pill services and solutions. Highlights of the company profiles include: • Company snapshot • Performance analysis (market revenue forecast) • Portfolio analysis • Key marketed products and patent expiry • SWOT analysis • Strategic analysis of growth levers